Iron therapy and severe arrhythmias in HFrEF: rationale, study design, and baseline results of the RESAFE‐HF trial. (17th January 2023)

• Record Type: Journal Article
• Authors: Bakogiannis, Constantinos; Mouselimis, Dimitrios; Tsarouchas, Anastasios; Papadopoulos, Christodoulos E.; Theofillogiannakos, Efstratios K.; Lechat, Elmira; Antoniadis, Antonios P.; Pagourelias, Efstathios D.; Kelemanis, Ioannis; Tzikas, Stergios; Fragakis, Nikolaos; Efthimiadis, Georgios K.; Karamitsos, Theodoros D.; Doumas, Michael; Vassilikos, Vassilios P.
• Is Part Of: ESC heart failure. Volume 10:Number 2(2023)
• Page Start: 1184
• Page End: 1192
• Publication Date: 2023-01-17
• Subjects: Heart failure -- HFrEF -- Iron deficiency -- Arrhythmia -- Ferric carboxymaltose -- FCM; Heart failure -- Periodicals; 616.129005
• DOI: 10.1002/ehf2.14276
• Languages: English
• ISSNs: 2055-5822

Abstract

Abstract: Aims: The Iron Intravenous Therapy in Reducing the burden of Severe Arrhythmias in HFrEF (RESAFE‐HF) registry study aims to provide real‐word evidence on the impact of intravenous ferric carboxymaltose (FCM) on the arrhythmic burden of patients with heart failure with reduced ejection fraction (HFrEF), iron deficiency (ID), and implanted cardiac implantable electronic devices (CIEDs). Methods and results: The RESAFE‐HF (NCT04974021) study was designed as a prospective, single‐centre, and open‐label registry study with baseline, 3, 6, and 12 month visits. Adult patients with HFrEF and CIEDs scheduled to receive IV FCM as treatment for ID as part of clinical practice were eligible to participate. The primary endpoint is the composite iron‐related endpoint of haemoglobin ≥ 12 g/dL, ferritin ≥ 50 ng/L, and transferrin saturation > 20%. Secondary endpoints include unplanned HF‐related hospitalizations, ventricular tachyarrhythmias detected by CIEDs and Holter monitors, echocardiographic markers, functional status (VO2 max and 6 min walk test), blood biomarkers, and quality of life. In total, 106 patients with a median age of 72 years (14.4) were included. The majority were male (84.9%), whereas 92.5% of patients were categorized to New York Heart Association II/III. Patients' arrhythmic burden prior to FCM administration was significant—19 patients (17.9%) received appropriate CIED therapy for termination of ventricular tachyarrhythmia in the preceding 12 months, and 75.5% of patients have frequent, repetitive multiform premature ventricular contractions. Conclusions: The RESAFE‐HF trial is expected to provide evidence on the effect of treating ID with FCM in HFrEF based on real‐world data. Special focus will be given on the arrhythmic burden post‐FCM administration.